Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia.

@inproceedings{Advani2009SouthwestOG,
  title={Southwest Oncology Group Study S0910: A Phase 2 Trial of Clofarabine/ Cytarabine/ Epratuzumab for Relapsed/ Refractory Acute Lymphocytic Leukemia.},
  author={Anjali S. Advani and Holly M Gundacker and Olga Sala-Torra and J. P. Radich and Raymond E Lai and Marilyn L. Slovak and Jeffrey E Lancet and Steve E Coutre and Robert K. Stuart and Martha P. Mims and Patrick J. Stiff and Frederick R. Appelbaum},
  year={2009}
}
Abstract 3094 Poster Board III-31 Clofarabine (Clo) has demonstrated single agent activity in acute lymphoblastic leukemia (ALL) and acute myeloid leukemia. Therefore, efforts have been undertaken to combine Clo with other antileukemic agents. Clo and cytarabine (Cy) target two different sites in DNA, have synergistic activity in vivo, and have non-overlapping toxicities, making this combination potentially promising for the treatment of relapsed/ refractory ALL. The maximum tolerated dose of… CONTINUE READING

Topics from this paper.

Citations

Publications citing this paper.
SHOWING 1-10 OF 13 CITATIONS

Current status of antibody therapy in ALL.

  • British journal of haematology
  • 2015
VIEW 1 EXCERPT

Agents for refractory/relapsed acute lymphocytic leukemia in adults.

  • European review for medical and pharmacological sciences
  • 2014

Novel Antibody Therapy in Acute Lymphoblastic Leukemia

  • Current Hematologic Malignancy Reports
  • 2014
VIEW 1 EXCERPT
CITES BACKGROUND